← brief for 2026-10-20 · Slowing decline

Real-world observational study evaluating metabolic and kidney outcomes in patients living with chronic kidney disease and type 2 diabetes mellitus with obesity prescribed tirzepatide.

Article C Peer reviewed Observational

Key takeaways

This study followed 62 adults with kidney disease and type 2 diabetes who started a weight-loss drug called tirzepatide. It is an observational study, which means it shows a link but not proof of cause. The researchers looked at how the drug affected their kidneys and metabolism in real life.

Who did this work

Carruthers JE · Ooi XY · Goodall D · Reed J · Bedi R · McGrath A · Willicombe M · Avari P · Frankel AH

Source

Article · PubMed, the drug frontier · 2026 Oct 19
https://pubmed.ncbi.nlm.nih.gov/42897718/